Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ida Paris

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
NPJ Breast Cancer|September 8, 2023
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancerAlessandra Fabi, Luisa Carbognin, Andrea Botticelli, et al.
Future Oncology (London, England)|June 14, 2025
Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK studyFranco Antonio, Luisa Carbognin, Ida Paris, et al.
Cancers|October 14, 2022
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-MakingFrancesco Pavese, Ettore Domenico Capoluongo, Margherita Muratore, et al.
Frontiers in Oncology|July 15, 2021
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity TrialFrancesco Schettini, Silvia Paola Corona, Fabiola Giudici, et al.
Oncotarget|October 4, 2017
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter studyAlessandra Fabi, Michelino De Laurentiis, Michele Caruso, et al.
Breast (Edinburgh, Scotland)|May 29, 2026
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER studyLetizia Pontolillo, Elisabetta Munzone, Paolo Vigneri, et al.
The Oncologist|November 23, 2023
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL StudyAndrea Botticelli, Roberta Caputo, Simone Scagnoli, et al.
Cancers|December 30, 2025
Pregnancy vs. Postpartum Breast Cancer: Distinct Tumor Biology and Survival Trends in a Contemporary CohortElena Jane Mason, Alba Di Leone, Beatrice Carnassale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trialGiampaolo Bianchini, Luca Malorni, Roberta Caputo, et al.
Breast (Edinburgh, Scotland)|August 10, 2018
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancerAlessandra Fabi, Daniele Alesini, Enrichetta Valle, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
NPJ Breast Cancer|September 8, 2023
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancerAlessandra Fabi, Luisa Carbognin, Andrea Botticelli, et al.
Future Oncology (London, England)|June 14, 2025
Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK studyFranco Antonio, Luisa Carbognin, Ida Paris, et al.
Cancers|October 14, 2022
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-MakingFrancesco Pavese, Ettore Domenico Capoluongo, Margherita Muratore, et al.
Frontiers in Oncology|July 15, 2021
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity TrialFrancesco Schettini, Silvia Paola Corona, Fabiola Giudici, et al.
Oncotarget|October 4, 2017
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter studyAlessandra Fabi, Michelino De Laurentiis, Michele Caruso, et al.
Breast (Edinburgh, Scotland)|May 29, 2026
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER studyLetizia Pontolillo, Elisabetta Munzone, Paolo Vigneri, et al.
The Oncologist|November 23, 2023
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL StudyAndrea Botticelli, Roberta Caputo, Simone Scagnoli, et al.
Cancers|December 30, 2025
Pregnancy vs. Postpartum Breast Cancer: Distinct Tumor Biology and Survival Trends in a Contemporary CohortElena Jane Mason, Alba Di Leone, Beatrice Carnassale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trialGiampaolo Bianchini, Luca Malorni, Roberta Caputo, et al.
Breast (Edinburgh, Scotland)|August 10, 2018
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancerAlessandra Fabi, Daniele Alesini, Enrichetta Valle, et al.
Pageof 10